An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Van der Jagt, Richard H. ^{[2
]}

Kahl, Brad S. ^{[3
]}

Wood, Peter ^{[4
]}

Hawkins, Tim E. ^{[5
]}

MacDonald, David ^{[6
,7
]}

Hertzberg, Mark ^{[8
]}

Kwan, Yiu-Lam ^{[9
]}

Simpson, David ^{[10
]}

Craig, Michael ^{[11
]}

Kolibaba, Kathryn ^{[12
]}

Issa, Samar ^{[13
]}

Munteanu, Mihaela C. ^{[14
]}

Clementi, Regina ^{[15
]}

Chen, Ling ^{[16
]}

Burke, John M. ^{[17
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Ottawa, Canadian Leukemia Studies Grp, Ottawa Hosp, Ottawa, ON, Canada

[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[4] Princess Alexandra Hosp, Dept Hematol, Woolloongabba, Qld 4102, Australia

[5] Auckland Hosp, Auckland 1023, New Zealand

[6] QEII Hlth Sci, Hematol, Halifax, NS, Canada

[7] Capital Dist Hlth Author, Halifax, NS, Canada

[8] Westmead Hosp, Westmead, NSW, Australia

[9] Concord Repatriat Gen Hosp, Sydney, NSW 2139, Australia

[10] N Shore Hosp, Auckland, New Zealand

[11] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA

[12] McKesson Specialty Hlth US Oncol Res, The Woodlands, TX USA

[13] Middlemore Hosp, Haematol Lymphoma Serv, Auckland 1640, New Zealand

[14] Teva Pharmaceut Ind Ltd, Clin Operat, Oncol & Immunol, Frazer, PA USA

[15] Teva Pharmaceut Ind Ltd, Amer Reg Clin Management, Global Clin Operat, Frazer, PA USA

[16] Teva Pharmaceut Ind Ltd, Biostat, Frazer, PA USA

[17] Rocky Mt Canc Ctr, Aurora, CO USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

902

引用

页数：3

共 50 条

[21] MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL).
Marcus, Robert E.
Solal-Celigny, Philippe
Imrie, Kevin
Catalano, John V.
Dmoszynska, Anna
Raposo, Joao C.
Offner, Fritz C.
Gomez-Codina, Jose
BLOOD, 2006, 108 (11) : 146A - 146A
[22] Phase 3 Study of Frontline Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Plus Vincristine (R-CHOP) or Bortezomib (VR-CAP) in Transplantation-Unsuitable Mantle Cell Lymphoma (MCL) Patients
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 9 - 11
[23] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
Wöhrer, S
Püspök, A
Drach, J
Hejna, M
Chott, A
Raderer, M
ANNALS OF ONCOLOGY, 2004, 15 (07) : 1086 - 1090
[24] PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS
Robak, T.
Huang, H.
Jin, J.
Zhu, J.
Liu, T.
Samoilova, O.
Pylypenko, H.
Verhoef, G.
Siritanaratkul, N.
Osmanov, E.
Alexeeva, J.
Pereira, J.
Mayer, J.
Hong, X.
Maeda, Y.
Pei, L.
Rooney, B.
van de Velde, H.
Cavalli, F.
HAEMATOLOGICA, 2014, 99 : 523 - 524
[25] Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
Strati, Paolo
Romaguera, Jorge E.
Kwak, Larry W.
Hagemeister, Fredrick B.
Rodriguez, Alma
Oki, Yasuhiro
Westin, Jason
Turturro, Francesco
Overman, Michael J.
Neelapu, Sattva S.
Fowler, Nathan
Fayad, Luis
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S145 - S146
[26] A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's Lymphoma
Cohen, Jonathon B.
Switchenko, Jeffrey
Koff, Jean L.
Sinha, Rajni
Kaufman, Jonathan L.
Khoury, H. Jean
Bumpers, Nassoma K.
Colbert, Amanda
Hutchison-Rzepka, Amanda A.
Nastoupil, Loretta J.
Heffner, Leonard T.
Langston, Amelia
Lechowicz, Mary Jo
Lonial, Sagar
Flowers, Christopher R.
BLOOD, 2014, 124 (21)
[27] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma
Lamar, Zanetta S.
Fino, Nora
Palmer, Jodi
Gruber, Lindsey
Morris, Bonny B.
Raetskaya-Solntseva, Olga
Kennedy, LeAnne
Vaidya, Rakhee
Hurd, David
Zamkoff, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (02): : 76 - 81
[28] Single institution retrospective study of infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, (EPOCH) plus /- rituximab (R) as first line therapy for aggressive non-Hodgkin lymphoma.
Lamar, Zanetta S.
Fitzgerald, Nora
Palmer, Jodi Michelle
Gruber, Lindsey
RaetskayaSolntseva, Olga
Kennedy, LeAnne
Vaidya, Rakhee
Zamkoff, Kenneth Warren
Hurd, David Duane
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[29] Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Marcus, Robert
Imrie, Kevin
Solal-Celigny, Philippe
Catalano, John V.
Dmoszynska, Anna
Raposo, Joao C.
Offner, Fritz C.
Gomez-Codina, Jose
Belch, Andrew
Cunningham, David
Wassner-Fritsch, Elisabeth
Stein, George
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4579 - 4586
[30] Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone plus /- Rituximab ( CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)
Kouroukis, Tom
Cheung, Winson Y.
Abdel-Samad, Nizar
Sehdev, Sandeep
Poulin-Costello, Melanie
Gillesby, Brad
Robson, Ewan J. D.
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →